Profiling of Serum Exosome MiRNA Reveals the Potential of a MiRNA Panel as Diagnostic Biomarker for Alzheimer’s Disease

Zhiwu Dong,Hongjun Gu,Qiang Guo,Shuang Liang,Jian Xue,Feng Yao,Xianglu Liu,Feifei Li,Huiling Liu,Li Sun,Kewen Zhao

DOI: https://doi.org/10.1007/s12035-021-02323-y

IF: 5.682

2021-02-24

Molecular Neurobiology

Abstract:Alzheimer’s disease (AD) is the most common neurodegenerative disease in the older adults. Although much effort has been made in the analyses of diagnostic biomarkers, such as amyloid-β, tau, and neurofilament light chain, identifying peripheral blood-based biomarkers is in extremely urgent need for their minimal invasiveness and more convenience. Here we characterized the miRNA profile by RNA sequencing in human serum exosomes from AD patients and healthy controls (HC) to investigate its potential for AD diagnosis. Subsequently, Gene Ontology analysis and pathway analysis were performed for the targeted genes from the differentially expressed miRNAs. These basic functions were differentially enriched, including cell adhesion, regulation of transcription, and the ubiquitin system. Functional network analysis highlighted the pathways of proteoglycans in cancer, viral carcinogenesis, signaling pathways regulating pluripotency of stem cells, and cellular senescence in AD. A total of 24 miRNAs showed significantly differential expression between AD and HC with more than ± 2.0-fold change at p value < 0.05 and at least 50 reads for each sample. Logistic regression analysis established a model for AD prediction by serum exosomal miR-30b-5p, miR-22-3p, and miR-378a-3p. Sequencing results were validated using quantitative reverse transcription PCR. The data showed that miR-30b-5p, miR-22-3p, and miR-378a-3p were significantly deregulated in AD, with area under the curve (AUC) of 0.668, 0.637, and 0.718, respectively. The combination of the three miRs gained a better diagnostic capability with AUC of 0.880. This finding revealed a miR panel as potential biomarker in the peripheral blood to distinguish AD from HC.

neurosciences

What problem does this paper attempt to address?

The problem this paper attempts to address is: finding peripheral blood-based diagnostic biomarkers for Alzheimer's disease (AD). Although some progress has been made in diagnostic biomarkers such as amyloid-β, tau protein, and neurofilament light chain, the detection of these markers usually requires invasive procedures like cerebrospinal fluid sampling. Therefore, finding biomarkers that can be detected through blood tests is particularly important. The authors aim to discover potential miRNA biomarkers for AD diagnosis by analyzing the miRNA expression profiles in serum exosomes of AD patients and healthy controls (HC).

Specifically, the main objectives of the paper include:
1. **Identification of differentially expressed miRNAs**: Using RNA sequencing technology, compare the miRNA expression profiles in serum exosomes of AD patients and healthy controls to identify significantly differentially expressed miRNAs.
2. **Functional annotation and pathway analysis**: Perform functional annotation and pathway analysis of the target genes regulated by the differentially expressed miRNAs to reveal the potential roles of these miRNAs in the pathogenesis of AD.
3. **Establishment of a diagnostic model**: Establish an AD prediction model based on differentially expressed miRNAs through logistic regression analysis and validate its diagnostic performance.

The core issue of the paper is to find non-invasive biomarkers for early AD diagnosis through the analysis of miRNA expression profiles in serum exosomes. This will help improve the sensitivity and accuracy of AD diagnosis, thereby providing better treatment opportunities for patients.